Search

Displaying results 811 - 820 of 4359 in total
  1. Drug

    Ipratropium

    go.drugbank.com/drugs/DB00332
    ApprovedInvestigational

    Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent. … [A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol

  2. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015.

  3. Drug

    Lomefloxacin

    go.drugbank.com/drugs/DB00978
    Approved

    Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.

  4. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia.

  5. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.

  6. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA.

  7. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. … [label] It is strongly advised that the risk-benefit ratio is considered before starting raloxifene therapy in women at risk of thromboembolic disease or strokes, such as the prior history of stroke, transient

  8. Drug

    Mepyramine

    go.drugbank.com/drugs/DB06691
    ApprovedVet approved

    However, it rapidly permeates the brain and so often causes drowsiness as a side effect.

    Mixtures: Trisulfaminic Sus
  9. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    [L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. … [A215082, A215092] Among treatment options, nucleoside analogues such as decitabine and [azacitidine] integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation

  10. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.